Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming daysRECCE® 327 now tested at four infusion times, achieving these...
March 13, 2024 19:30 ET | Source: Mesoblast Limited

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm...
March 13, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting

SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
March 12, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance

SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
March 11, 2024 17:31 ET | Source: Telix Pharmaceuticals Limited

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief...
March 11, 2024 11:39 ET | Source: Imugene Limited

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Phase 1 trial of CD19 oncolytic virotherapy drug candidate onCARlytics cleared its first cohort within the intratumoral monotherapy arm of the study.
March 10, 2024 19:54 ET | Source: Mesoblast Limited

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA...
March 10, 2024 17:00 ET | Source: Euro Manganese Inc.

Euro Manganese geht in die nächste Phase des Fremdfinanzierungsverfahrens mit der Europäischen Investitionsbank über

VANCOUVER, British Columbia, March 10, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V und ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (das „Unternehmen“) gab heute die offizielle Aufnahme seines...
March 10, 2024 17:00 ET | Source: Euro Manganese Inc.

Euro Manganese Advances to Next Stage of Debt Funding Process with the European Investment Bank

VANCOUVER, British Columbia, March 10, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company") today announced that its Chvaletice Manganese...
March 07, 2024 17:19 ET | Source: Novonix Ltd.

NOVONIX Releases Inaugural Sustainability Report

BRISBANE, Australia, March 08, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that...